Insider trade

Officer sold ~$1.2M of JAZZ shares in the open market

Traded Nov 17, 2025 · Filed Nov 20, 2025

Why it stands out

Jazz Pharmaceuticals's Global Head of R&D & CMO sold $1.2M of Jazz Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,204,573

Shares × reported transaction price

Timing vs results

12 days after results of Nov 5, 2025, 56 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.2%	+3.7%	−3.9%
30 days	−4.1%	+3.9%	−8.0%
90 days	−4.2%	+3.9%	−8.0%
180 days	+35.1%	+12.5%	+22.6%

Past results only. Not a forecast.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025.

Officer sold

10mo ago

Jazz Pharmaceuticals's SVP, Technical Operations sold $379K of Jazz Pharmaceuticals shares. Nobody planned it ahead of time.

10mo ago

Routine share withholding; mechanical by default.

Automatic sale10mo ago